Drug Trial Radar · NCT06944925
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
May 8, 2025
Primary completion
Jan 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Bambusa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
BBT002Drug
BBT002 will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events following single and multiple administration of BBT002Time frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
- Number of participants with change in Laboratory assessmentsTime frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
- Number of participants with change in vital sign measurements following dose administration.Time frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
- Number of participants with change in physical examination following dose administration.Time frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
- Number of participants with change in 12-lead ECG readingsTime frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Equity Medical Bowling Green
Bowling Green, Kentucky · Recruiting
Equity Medical - Owensboro
Owensboro, Kentucky · Not yet recruiting
Equity Medical LLC
New York, New York · Recruiting
Momentum Clinical Research
Brisbane, Australia · Recruiting
Linear Clinical Research
Perth, Western Australia, Australia · Recruiting
Aleksandre Aladashvili Clinic LLC
Tbilisi, Georgia · Recruiting
Geo Hospitals Tbilisi Multiprofile Medical Center
Tbilisi, Georgia · Recruiting
LEPL The First University Clinic of Tbilisi State Medical University
Tbilisi, Georgia · Recruiting
Ltd Aversi Clinic
Tbilisi, Georgia · Recruiting
Momentum Clinical Research
Pukekohe, New Zealand · Recruiting
Momentum Clinical Research
Wellington, New Zealand · Recruiting
Momentum Clinical Research Hamilton
Rotorua, Hamilton, New Zealand · Not yet recruiting
Uniwersyteckie Centrum Kliniczne Osrodka Badan Klinicznych Wczesnych Faz
Gdansk, Poland · Not yet recruiting
Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.
Krakow, Poland · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.